We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma.
- Authors
Hoff, Paulo M.; Wolff, Robert A.; Bogaard, Karla; Waldrum, Sherry; Abbruzzese, James L.
- Abstract
Background: One of the most studied pro-angiogenic factors involved in the development of colorectal cancer is the vascular endothelial growth factor (VEGF). The small molecule tyrosine kinase inhibitor semaxanib (SU5416) is one of the several agents targeting the VEGF signaling pathway, and its development centered mostly in the treatment of colorectal cancer.
- Publication
Japanese Journal of Clinical Oncology, 2006, Vol 36, Issue 2, p100
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyi229